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The pathogenetic mechanism of the deafness-associated mitochondrial DNA (mtDNA) T7445C mutation has
been investigated in several lymphoblastoid cell lines from members of a New Zealand pedigree exhibiting the
mutation in homoplasmic form and from control individuals. We show here that the mutation flanks the 3* end
of the tRNASer(UCN) gene sequence and affects the rate but not the sites of processing of the tRNA precursor.
This causes an average reduction of ;70% in the tRNASer(UCN) level and a decrease of ;45% in protein
synthesis rate in the cell lines analyzed. The data show a sharp threshold in the capacity of tRNASer(UCN) to
support the wild-type protein synthesis rate, which corresponds to ;40% of the control level of this tRNA.
Strikingly, a 7445 mutation-associated marked reduction has been observed in the level of the mRNA for the
NADH dehydrogenase (complex I) ND6 subunit gene, which is located ;7 kbp upstream and is cotranscribed
with the tRNASer(UCN) gene, with strong evidence pointing to a mechanistic link with the tRNA precursor
processing defect. Such reduction significantly affects the rate of synthesis of the ND6 subunit and plays a
determinant role in the deafness-associated respiratory phenotype of the mutant cell lines. In particular, it
accounts for their specific, very significant decrease in glutamate- or malate-dependent O2 consumption.
Furthermore, several homoplasmic mtDNA mutations affecting subunits of NADH dehydrogenase may play a
synergistic role in the establishment of the respiratory phenotype of the mutant cells.
Cochlear function depends on a very high rate of ATP
production, and mitochondrial DNA (mtDNA)-dependent
dysfunctions have often been found to cause hearing defects
either in syndromic or nonsyndromic form. mtDNA-linked
deafness exhibits in high degree the characteristics of tissue
specificity and variable degree of penetrance which are a hall-
mark of mtDNA mutation-dependent disorders, most typically
of Leber’s hereditary optic neuropathy (LHON) (19, 20, 23, 24,
43). Among the identified deafness-causing mtDNA mutations
are an A-to-G transition at position 1555 (A1555G) in the 12S
rRNA gene (10, 21, 32), a heteroplasmic C-nucleotide inser-
tion at position 7472 in the tRNASer(UCN) gene (39), and a
T-to-C transition at position 7445 (T7445C) in the DNA se-
quence encoding the precursor of this tRNA. The latter mu-
tation has been described in members of a Scottish maternal
pedigree with sensorineural bilateral hearing loss (34) and in
New Zealand and Japanese pedigrees with sensorineural hear-
ing loss and palmoplantar keratoderma (11, 38). The three
pedigrees are unrelated, exhibiting distinct sets of mtDNA
polymorphisms (11, 35, 38), besides the identical mutation at
position 7445. This mutation changes the stop codon AGA of
the heavy-strand (H-strand)-encoded mRNA for subunit COI
of cytochrome c oxidase (3, 29, 30) to an equivalent AGG stop
codon, and at the same time, causes a U-to-C transition in the
light-strand (L-strand)-encoded tRNASer(UCN) precursor (3,
29).
The occurrence of a mutation at position 7445 in three
genetically unrelated pedigrees affected by sensorineural deaf-
ness and differing considerably in their mtDNA haplotype is
clear evidence that this mutation is involved in the pathogen-
esis of the disorder (11, 33, 38). A recent investigation of a
lymphoblastoid cell line derived from a deaf member of the
Scottish family carrying the mutation at position 7445 in ho-
moplasmic form compared to a control cell line revealed a
marked decrease (60 to 65%) in its tRNASer(UCN) content,
which was suggested to result from a decrease in the efficiency
of processing of the mutant tRNA precursor. However, no
abnormality in mitochondrial protein synthesis nor any signif-
icant impairment of respiratory function was reported for this
cell line (33).
In order to investigate further the pathogenetic mechanism
of the mutation in the New Zealand family, in the present
work, lymphoblastoid cell lines derived from four members of
this family and from four control individuals have been ana-
lyzed. It has been shown that the mutation at position 7445,
flanking the 39 end of the tRNASer(UCN) sequence, affects the
rate of processing of the tRNA precursor. This produces a
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drastic decrease in the steady-state level of this tRNA, with
significant effects on protein synthesis. Furthermore, a specific
marked reduction in the level of the ND6 mRNA has been
shown to be associated and probably mechanistically linked
with the mtDNA mutation at position 7445 and to play a
determinant role in the respiratory phenotype of the mutant
cells.
MATERIALS AND METHODS
Cell lines and media. Eight human immortalized lymphoblastoid cell lines,
derived from four members of the New Zealand family exhibiting the mutation
at position 7445 and various degrees of hearing loss (individuals IV-5, IV-7,
IV-15, and V-7; the Roman number indicates the generation in the pedigree
[11]), and from four genetically unrelated individuals (0913, 0923, 1032, and
0615) lacking the mutation at position 7445 as well as the five additional changes
from the Cambridge mtDNA sequence (2) found in the New Zealand family
haplotype (11), were used in this work. The cells were grown either in a specially
made Dulbecco’s modified Eagle medium (DMEM) containing 1 mg of glucose
per ml, 0.11 mg of pyruvate per ml, and 0.36 mM CaCl2 (hereafter referred to as
special DMEM-glucose), supplemented with 10% fetal bovine serum (FBS) or in
the same medium lacking glucose but containing 0.9 mg of galactose and 0.5 mg
of pyruvate per ml (hereafter referred to as special DMEM-galactose), supple-
mented with 10% dialyzed FBS. The bromodeoxyuridine-resistant 143B.TK2
cells (25) were grown in regular DMEM (containing 4.5 mg of glucose and 0.11
mg of pyruvate per ml), supplemented with 100 mg of bromodeoxyuridine per ml
and 5% FBS. VA2B cells were grown in DMEM supplemented with 10% bovine
serum. The population doubling times (DTs) of the cell lines in special DMEM-
glucose or special DMEM-galactose were determined as previously detailed (14).
mtDNA analysis. Total DNA samples were isolated from the cultured lym-
phoblastoid cell lines and from 143B.TK2 cells with an Applied Biosystems 340A
DNA extractor. The A-to-G transition in mtDNA at position 7445 of the Cam-
bridge sequence (3) was detected by taking advantage of the mutation-associated
loss of the XbaI site as previously described (11), except for the use of oligode-
oxynucleotides corresponding to positions 7396 to 7417 and 7657 to 7676 for the
PCR amplification of an appropriate mtDNA fragment.
The quantification of mtDNA was performed by slot blot hybridization, using
a 32P-labeled human mtDNA fragment as a specific probe and a 32P-labeled
nuclear 28S rRNA gene fragment as a normalization probe, as previously de-
scribed (14). Quantification of the hybridization was carried out by scanning the
fluorograms by laser densitometry or by analyzing the slot blot in a Phospho-
rImager (Molecular Dynamics). For comparison of the data from different blots,
the values obtained for the lymphoblastoid cell lines in each blot were normal-
ized to the values obtained for the 143B.TK2 sample in the same blot.
Isolation of mitochondrial and total cell RNA. Total mitochondrial nucleic
acid preparations were obtained by acid phenol-chloroform extraction from
mitochondria isolated from lymphoblastoid cell lines (;3.0 3 108 cells), and
from twice EDTA-washed mitochondria of HeLa cells (;3.0 3 109 cells), as
previously described (26). Highly purified total mitochondrial tRNA prepara-
tions were obtained from mitochondrial nucleic acids extracted from HeLa cells
and from the IV-5 mutant lymphoblastoid cell line by polyacrylamide gel elec-
trophoresis (PAGE), as previously detailed (26). The tRNA fraction isolated by
the latter method was used for synthesizing, cloning, and sequencing the cDNA
corresponding to tRNASer(UCN), while the total mitochondrial nucleic acid frac-
tions were used for quantification of the mitochondrial tRNAs and 12S rRNA.
Total cell RNA was isolated by the RNAzol B procedure (TEL-TEST, Inc.,
Friendswood, Tex.) which is based on a modification of the single-step method
by acid guanidinium thiocyanate-phenol-chloroform extraction (7).
Sequencing of 5*- and 3*-end proximal segments of tRNASer(UCN). The 59 and
39 ends of the mitochondrial tRNASer(UCN) from HeLa cells and from the
mutant cell line IV-5 were sequenced after cDNA synthesis, PCR amplification,
and cloning, as described elsewhere (46). First, highly purified total mitochon-
drial tRNA was circularized by incubation in the presence of T4 RNA ligase
(Promega) to ligate the 39 and 59 ends of the tRNAs. Then, a complementary
DNA chain of the tRNASer(UCN) was synthesized by reverse transcriptase after
annealing of the circular tRNA with the specific oligodeoxynucleotide SUCN4
(59-CAAGCCAACCCCATGGCCTC-39). The second strand of this cDNA was
synthesized by using the primer SUCN3 (59-AAACCAGCTTTGGGGGGTTC-
39), and the artificial tDNA was then amplified by PCR, using both oligode-
oxynucleotides SUCN3 and SUCN4. Subsequently, the PCR product was cloned
in the TA vector (Invitrogen), and eight clones of HeLa cell tDNA and five
clones of IV-5 tDNA were sequenced by the ABI PRISM Dye Terminator Cycle
Sequencing Core (Perkin Elmer).
Quantification of the mitochondrial tRNASer(UCN). To determine the cell con-
tent of the mitochondrial tRNASer(UCN), tRNALeu(UUR), tRNALys, tRNAGln,
tRNAGlu, and 12S rRNA in all cell lines for use as reference markers, total
mitochondrial nucleic acid preparations were electrophoresed through a 5%
polyacrylamide–7 M urea gel in Tris-borate-EDTA buffer (TBE) (after heating
the sample at 90°C for 5 min) and then electroblotted onto a Zeta-probe mem-
brane (Bio-Rad) for hybridization analysis with specific oligodeoxynucleotide
probes. For the detection of tRNASer(UCN), tRNALys, tRNALeu(UUR), tRNAGln,
tRNAGlu, and 12S rRNA, the following 59-end 32P-labeled oligodeoxynucleoti-
des specific for each RNA were used: 59-CAAGCCAACCCCATGGCCTC-39
(tRNASer(UCN)); 59-TCACTGTAAAGAGGTGTTGG-39 (tRNALys); 59-TGTT
AAGAAGAGGAATTGAA-39 (tRNALeu(UUR)); 59-CTAGGACTATGAGAA
TCGAA-39 (tRNAGln); 59-TATTCTCGCACGGACTACAA-39 (tRNAGlu); and
59-GAAAGGCTAGGACCAAACCTA-39 (12S rRNA). The hybridization reac-
tions were carried out in a mixture of 63 SSC (SSC is standard saline citrate; 13
SSC is 150 mM NaCl plus 15 mM trisodium citrate), 53 Denhardt’s solution,
0.1% sodium dodecyl sulfate (SDS), and 200 mg of salmon sperm DNA per ml,
for 6 h at 37°C. After hybridization, the samples were washed two times for 10
min in 23 SSC–0.1% SDS at 37 or 50°C. The radioactivity in each band was
quantified as detailed above for slot blot hybridization.
mRNA analysis. For RNA transfer hybridization analysis, 20 mg of total cell
RNA was fractionated by electrophoresis through a 1.4% agarose–2.2 M form-
aldehyde gel (8), transferred to a Zeta-probe membrane (Bio-Rad), and hybrid-
ized with a [32P]dCTP-labeled single-stranded (ss) ND6-specific DNA probe
(which was synthesized on XbaI-linearized pND6-1 plasmid by using the Klenow
fragment of polymerase I and the SP6 primer). After the blot was stripped, the
RNA was hybridized with total purified HeLa cell mtDNA, which had been
[32P]dCTP labeled by random priming. After the blot was restripped, the RNA
was rehybridized with a [32P]CTP-labeled ND6-specific RNA probe synthesized
on the pND6-1 plasmid with SP6 RNA polymerase. The plasmid pND6-1 was
constructed by amplifying a 275-bp fragment of the human ND6 gene (positions
14343 to 14618) by PCR, cloning it in the TA vector (Invitrogen), and subcloning
the 280-bp EcoRI insert into the pGEM-7Zf(1) vector carrying the SP6 and T7
promoters (Promega).
Analysis of mitochondrial protein synthesis. Pulse-labeling of the cell lines for
30 min with [35S]methionine-[35S]cysteine in the presence of emetine, electro-
phoretic analysis of the translation products, and quantification of radioactivity
in the whole electrophoretic patterns or in individual bands was carried out as
detailed previously (14). Labeling of mitochondrial translation products with
[3H]serine (30 Ci mmol21; 50 mCi/ml) for 30 min in serine-free special DMEM-
glucose, electrophoretic analysis of the samples, and treatment of the gels were
carried out in the same way.
O2 consumption measurements. Rates of O2 consumption were determined
with a Gilson 5/6 oxygraph on samples of 107 cells in 1.5-ml portions of special
DMEM-glucose lacking glucose supplemented with 10% dialyzed FBS (25).
Polarographic analysis of digitonin-permeabilized cells with different respiratory
substrates and inhibitors to test the activity of the various respiratory complexes
was carried out as detailed elsewhere (18).
Computer analysis. Variance analysis was performed by the analysis of vari-
ance (ANOVA) test contained in the StatView program for Macintosh (version
4.0) (SAS Institute) and entering individual replicate values. Curve fitting for Fig.
5c was done with the program PSI-Plot (Poly Software International).
RESULTS
The New Zealand pedigree and derived lymphoblastoid cell
lines. The pedigree of the New Zealand family with maternally
inherited deafness has been previously described (11, 38). Im-
mortalized lymphoblastoid cell lines were derived from four
members of this family exhibiting the mutation at position
7445, three individuals with moderate to profound sensorineu-
ral deafness (IV-5, IV-7, and IV-15; all three between 25 and
31 years old), and one individual with mild conductive deafness
(V-7; 11 years old) and from four genetically unrelated indi-
viduals lacking the mutation (0913, 0923, 1032, and 0615; all
four between 28 and 35 years old) (11). The presence of the
mutation in the four chosen lymphoblastoid cell lines from
the New Zealand pedigree has been confirmed in the pres-
ent work, and in all cell lines, the mutation appeared to be
homoplasmic.
A complete sequence analysis of the mtDNA from one ped-
igree member (11) had previously revealed, besides the muta-
tion at position 7445, five additional sequence changes from
the Cambridge consensus sequence (3). Of these changes, two,
the T4216C transition in the ND1 gene and the G13708A tran-
sition in the ND5 gene, have been observed to occur with
increased frequency in LHON patients (22). A T-to-C transi-
tion at position 10084 in the ND3 gene represents a rare novel
mutation, while the G-to-A transition at position 3010 in the
16S rRNA gene and the T-to-C transition at position 14798
in the apocytochrome b gene are polymorphisms commonly
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found in controls. These five additional sequence changes were
absent in the four control cell lines utilized in this study.
Mutation site. The U-to-C transition at position 7445 in
the L-strand-encoded tRNASer(UCN) precursor was original-
ly thought to be located in the 39-terminal nucleotide of the
tRNASer(UCN) (11, 34) on the basis of the proposed structure
for this tRNA (2), as deduced from the Cambridge mtDNA
sequence (3). However, structural studies on bovine mitochon-
drial tRNASer(UCN) (47) have led to a reinterpretation of the
original sequence, which would place the human nucleotide
(nt) 7445 to a position immediately adjacent on the 39 side to
the encoded tRNASer(UCN) (33, 39).
To verify in human mtDNA the position of the 7445 muta-
tion relative to the tRNASer(UCN) coding sequence, as well
as to investigate the possible effect of the mutation on the
tRNASer(UCN) precursor processing, cDNA clones derived
from circularized tRNASer(UCN) (46) from wild-type (HeLa)
cells and from a mutant cell line (IV-5) were sequenced.
Figure 1a shows the expected structure of the circularized
tRNASer(UCN) molecule, as deduced from the original inter-
pretation of the Cambridge mtDNA sequence (2) and from the
revised interpretation (47). Figure 1b shows the sequence de-
termined for the 59-39 junction sequence in eight cDNA clones
from HeLa cell tRNASer(UCN) and five clones from the mutant
IV-5 cell tRNASer(UCN). Both sequences lack nt 7445, which is
fully consistent with the revised model. Furthermore, no dif-
ference was observed between the wild-type and the mutant
59-39 junction sequence. Other experiments, involving in vitro
processing by partially purified human mitochondrial RNase P
of in vitro-transcribed tRNASer(UCN) showed that this tran-
script was cleaved at a position 39 to nt 7515, which fully
supports the sequencing data (32a). Figure 1c shows the ex-
perimentally determined processing site for mitochondrial
RNase P in the tRNASer(UCN) precursor and the 39 endonu-
clease processing site expected on the basis of the sequencing
data.
The fact that the A7445G transition affects the 39-end nu-
cleotide of the stop codon (AGA) of the COI coding sequence
in the H-strand polycistronic transcript (3, 29, 30) raised the
possibility of alterations in the processing of this transcript.
However, RNA transfer hybridization experiments utilizing
total cell RNA and 32P-labeled human mtDNA as a probe
failed to show any mobility change or quantitative change in
the COI mRNA or its precursor (RNA 6) (29, 30) or the
presence of any abnormally migrating band (data not shown),
in confirmation of previous findings (33).
Marked decrease in amount of tRNASer(UCN). It seemed
possible that the rate of processing of the tRNASer(UCN) from
its precursor is affected by the mutation at position 7445. To
test this possibility, the influence of the U7445C transition on
the steady-state level of the tRNASer(UCN) was investigated.
For this purpose, equal amounts of total mitochondrial nucleic
acids (26) from the control and mutant cell lines were run in
parallel on a 5% polyacrylamide–7 M urea gel, electroblotted,
and hybridized with a 59-end 32P-labeled oligodeoxynucleotide
probe specific for mitochondrial tRNASer(UCN) (9). This tRNA
did not show any obvious size change in mutant cells, but the
amount decreased markedly from that in control cells (Fig. 2a).
For comparison, the levels of several other mtDNA-coded
RNAs derived from the three transcription units of the human
mitochondrial genome (27, 28) (Fig. 3) were determined. In
particular, the levels of tRNALeu(UUR) and tRNALys (Fig. 2a)
(as representatives of the whole H-strand transcription unit
[Fig. 3]) and of two tRNAs derived from the L-strand tran-
scription unit [encoded in a region either upstream (tRNAGlu)
or downstream (tRNAGln) relative to tRNASer(UCN) (Fig. 3)]
were quantified in the control and mutant cell lines on the
same blot, after stripping it, using 59-end 32P-labeled specific
oligodeoxynucleotide probes. Similarly, the levels of 12S rRNA,
as representative of the H-strand rDNA transcription unit
(Fig. 3), in the two groups of cell lines were determined in a
blot of total mitochondrial nucleic acids. The average levels of
tRNASer(UCN) obtained in the various control or mutant cell
lines were then normalized to the average levels determined in
the same cell lines for each of the reference RNAs. The aver-
age tRNASer(UCN) content values in the different mutant cell
lines, normalized to the individual reference RNA levels, when
expressed relative to the corresponding average values found
in the control cell lines, were remarkably similar, ranging be-
tween ;25% (after normalization to the tRNALeu(UUR) level)
and ;30% (after normalization to the tRNAGln and 12S rRNA
levels) (Fig. 2b). These values reflected a very significant de-
crease in tRNASer(UCN) content in mutant cells relative to the
controls (P , 0.0001 to P 5 0.0030 by the ANOVA test). The
average tRNASer(UCN) content values in the individual mutant
cell lines were 28, 38, 27, and 23% of the overall average
control value in IV-15, IV-7, IV-5, and V-7, respectively. The
average tRNASer(UCN) content values in the individual control
cell lines, expressed relative to the same overall average con-
FIG. 1. Site of the mutation at position 7445 in the mitochondrial tRNASer(UCN)
precursor and effect of the mutation on tRNA processing. (a) Structure of
circularized tRNA according to the Cambridge model (2) and the revised model
(47). SUCN4 and SUCN3 indicate the two oligonucleotides utilized for the
synthesis of the first and second strands of the cDNA, respectively. (b) Sequence
of the 59-39 end junction determined in eight cDNA clones from wild-type (WT)
HeLa cell mitochondrial tRNASer(UCN) and five cDNA clones from the mito-
chondrial tRNASer(UCN) of the mutant (MT) lymphoblastoid cell line IV-5. (c)
Processing sites in the mitochondrial tRNASer(UCN) precursor, experimentally
determined for RNase P and predicted from the sequencing data for the 39
endonuclease.
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trol value, were 101, 107, 114, and 79% in 0913, 0923, 1032, and
0615, respectively.
An investigation of the mtDNA content of these cell lines by
slot blot hybridization, carried out using a 32P-labeled human
mtDNA probe and a human 28S rRNA gene probe for nor-
malization purposes, failed to reveal any significant difference
between the average mtDNA/ribosomal DNA (rDNA) ratio
for the control cell lines and the average (P 5 0.4989) (Fig. 2b),
as well as the individual values (not shown), for the mutant cell
lines. Therefore, the observed decreases in the tRNASer(UCN)
levels in the mutants relative to those in the control cell lines
do not appear to reflect differences in the amount of mtDNA
template.
Mitochondrial protein synthesis defects. The SDS-PAGE
patterns of the mitochondrial translation products from the
U7445C mutation-carrying lymphoblastoid cell lines differ
from those of the control lymphoblastoid cell lines and from
that of the human osteoblastoma-derived cell line 143B.TK2
(25) by the faster migration of the ND1 and ND3 polypeptides
(Fig. 4a and c). This higher mobility presumably reflects the
occurrence of mutations in the reading frames for these poly-
peptides which was mentioned above. The VA2B cell line,
which is related to HeLa cells, shows an even greater electro-
phoretic mobility of ND3 (Fig. 4a). This abnormal migration of
the ND3 polypeptide in HeLa cells and related cell lines has
been observed before (45) and shown to be associated with a
different mutation of the ND3 reading frame (31). The poly-
peptide A8 of the control 0923 cell line shows a reduced mo-
bility from that in the other cell lines (Fig. 4b). This change
presumably results from the occurrence in this polypeptide of
a G-to-A transition at position 8519, producing a Glu-to-Lys
change, and a C-to-A transversion at position 8546, producing
a Leu-to-Ile change.
The cell lines carrying the mutation at position 7445 showed
a clear, although variable, decrease in the overall rate of la-
beling of the translation products relative to the control lym-
FIG. 2. Determination of the amount of mitochondrial tRNASer(UCN) and of
the mtDNA content in control and mutant lymphoblastoid cell lines. (a) Equal
amounts of total mitochondrial nucleic acid samples from the various cell lines
were electrophoresed under nonacid conditions, electroblotted, and hybridized
with 59-end 32P-labeled oligonucleotide probes specific for the mitochondrial
tRNASer(UCN), tRNALys, and tRNALeu(UUR). (b) Average relative mitochon-
drial tRNASer(UCN) content per cell, normalized to the average content per cell
of mitochondrial tRNALeu(UUR), tRNALys, tRNAGln, tRNAGlu, or 12S rRNA in
the four control cell lines and in the four mutant cell lines. The values for the
latter are expressed as percentages of the average values for the control cell lines.
The calculations were based on one to three independent determinations of
tRNASer(UCN) content in each cell line and on one to three determinations of the
content of each of the five reference RNA markers in two control cell lines (0913
and 1032) and two mutant cell lines (IV-7 and IV-5) and of the content of
tRNALeu(UUR) and 12S rRNA in the other two control cell lines (0615 and 0923)
and two mutant cell lines (IV-15 and V-7). The average mtDNA content per cell
in the mutant cell lines, normalized relative to the hybridization to a nuclear 28S
rRNA probe and expressed as a percentage of the average value determined in
the control cell lines, is also shown. Six mtDNA determinations were made
for each cell line. See Materials and Methods for details. The error bars
indicate two standard errors of the mean; P indicates the significance, ac-
cording to the ANOVA test, of the difference between mutant and control
values for tRNASer(UCN) normalized to the values for each reference marker.
FIG. 3. Genetic and transcription maps of the human mitochondrial genome.
The two inner circles show the positions of the two rRNA genes, 16S and 12S
(black bars), of the reading frames (white bars) and of the tRNA genes (solid
circles). The outer portion of the diagram shows the transcripts of the whole
H-strand transcription unit (black bars), the H-strand rDNA transcription unit
(white bars), and the L-strand transcription unit (hatched bars; in the three
longest ones, RNAs 1, 2 and 3, and in ND6 mRNA, the black portion represents
the ND6 reading frame). COI, COII, and COIII are subunits I, II, and III of
cytochrome c oxidase, respectively; ND1, ND2, ND3, ND4, ND4L, ND5, and
ND6 are subunits 1, 2, 3, 4, 4L, 5, and 6 of the respiratory chain NADH
dehydrogenase, respectively; and A6 and A8 are subunits 6 and 8 of the H1-
ATPase. cyt.b, apocytochrome b; OH and OL, origin of H-strand and L-strand
synthesis, respectively, with arrows indicating the direction of synthesis; F-met,
formylmethionyl.
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phoblastoid cell lines (Fig. 4). This decrease ranged between
15 (IV-7) and 75% (V-7), with an average of ;45% (P ,
0.0001 by the ANOVA test) (Fig. 5a). No abnormal mitochon-
drial translation products were observed in the mutant cell
lines, as previously found in the cell lines carrying the myo-
clonic epilepsy and ragged-red fiber (MERRF) tRNALys mu-
tation at position 8344 (9). However, it was possible that al-
terations in the posttranscriptional modifications of the
tRNASer(UCN) related to the reduced rate of processing of the
tRNA precursor could cause misincorporation of other amino
acids at serine (UCN) codons or inappropriate incorporation
of serine residues. To test this possibility, the 0913 and 1032
control cell lines and the IV-5 and IV-7 mutant cell lines were
pulse-labeled for 30 min with [3H]serine, and their mitochon-
drial translation products were analyzed by SDS-PAGE. Pro-
tein labeling decreased by 13.5% in IV-7 cells and 46.4% in
IV-5 cells relative to the average control labeling; these de-
creases are comparable to those observed in the same cell lines
for the [35S]methionine labeling (15 and 52%, respectively).
Moreover, all the products of the mutant cell lines were la-
beled with [3H]serine in the same relative proportion as in the
control cell lines, arguing against either an excess or deficiency
of serine incorporation in any of the polypeptides synthesized
by mutant cells relative to the expected pattern (data not
shown).
The average labeling of each polypeptide in the mutant cell
lines, relative to that in the control cell lines, after a 30-min
pulse with [35S]methionine, was decreased by 33 to 50%, ex-
cept that of ND6, which was decreased by ;59% (Fig. 5b).
Interestingly, the reduction in labeling of the various polypep-
tides did not vary in relationship to the number of serine
(UCN) codons in the corresponding mRNAs. In this respect,
the behavior of the rate of synthesis versus serine content of
the individual polypeptides was dramatically different from the
changes in rate of synthesis as related to polypeptide lysine
content which had been previously observed in cell lines car-
rying in nearly homoplasmic form the tRNALys mutation at
position 8344 associated with MERRF encephalomyopathy
(9). In the latter case, the data indicated clearly an exponential
decrease in the rate of synthesis of the individual mitochon-
drial translation products with increasing lysine content, as a
result of a ;26% probability for a ribosome to fall off the
mRNA at or near each lysine codon, releasing the incomplete
polypeptide (9). It was therefore hypothesized that the differ-
ent results obtained in U7445C mutation-carrying cells reflect-
ed the fact that the ribosomes did not fall off the mRNA at or
near each serine codon but simply stalled for a certain time due
to the deficiency of aminoacylated tRNASer(UCN) and then
resumed elongation in the proper frame.
As shown in Fig. 5c, the experimentally determined labeling
rates of all polypeptides, except ND6, when related to the pro-
portion of serine (UCN) codons in the corresponding mRNAs,
FIG. 4. Electrophoretic patterns of the mitochondrial translation products of the lymphoblastoid cell lines, VA2B cells, and 143B.TK2 (143B) cells labeled for 30
min with [35S]methionine in the presence of 100 mg of emetine per ml. Samples containing equal amounts of protein (30 mg), except the 143B.TK2 and VA2B samples,
which contained 15 mg of protein, were run through SDS–15 to 20% exponential polyacrylamide gradient gels. The three panels represent electrophoretic patterns
obtained in separate gel runs, each one including the 143B.TK2 control for normalization purposes. The intensities of the bands were quantified by densitometric
analysis of appropriate exposures of the fluorograms. The faster migration of the ND1 and ND3 polypeptides is indicated by the arrows in panels a and c. For an
explanation of abbreviations, see the legend to Fig. 3.
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conformed well (P , 0.01) to the equation Rx 5 R0 {0.1/[0.1
(1 2 x) 1 1.5x]} (R0 5 100.8), which describes the transient-
pause model mentioned above. In this equation, Rx is the rate
of synthesis of a given polypeptide in mutant cells relative to
the rate in wild-type cells, both rates being expressed as recip-
rocals of the times required for their synthesis, and x is the
proportion of serine (UCN) codons in the mRNA coding for
the polypeptide. According to the equation, amino acids other
than those specified by Ser (UCN) codons are assumed to be
incorporated into the growing polypeptide chain at an average
of one per 0.1 s and serine residues specified by UCN codons
are incorporated at the same rate in wild-type cells; by con-
trast, in U7445C mutation-carrying cells, serine (UCN) resi-
dues are assumed to be incorporated at a rate of one per 1.5 s
due to the deficiency of aminoacylated tRNASer(UCN) and the
consequent pausing of the ribosomes at each serine (UCN)
codon. While an average rate of incorporation of one amino
acid per 0.1 s is a reasonable one for mitochondrial protein
synthesis in human cells (unpublished observations), it should
be emphasized that the critical parameter in the equation given
above is the ratio of the rate of incorporation of amino acids
other than serine residues specified by UCN codons to the rate
of incorporation of such serine residues in mutant cells. The
value of 1.5 s for the rate of incorporation of serine (UCN)
residues in mutant cells was arrived at by trial and error as that
which best fitted the data. It should be noted that the curve
describing the equation given above extrapolates to about
100% rate of synthesis for a polypeptide lacking serine (UCN)
residues. This would imply that, if the model underlying the
equation is correct, there are no significant effects on the rate
of mitochondrial protein synthesis of factors other than the
proportion of serine residues. A very significant observation is
that the rate of synthesis of the ND6 polypeptide deviated
markedly from the curve describing the equation given above
(Fig. 5c); this value was not considered in constructing the
curve best fitting the other data. The origin of this deviation is
discussed below.
Significant decrease in ND6 mRNA level. The more marked
decrease in the rate of ND6 synthesis in the mutant relative to
the control cell lines than predicted from the transient-pause
model called attention to a possible decrease in the amount of
ND6 mRNA in mutant cells. Both tRNASer(UCN) and the ND6
mRNA are transcribed from the mtDNA L-strand and are
derived from the processing of large polycistronic transcripts
(29, 30) (Fig. 3). In order to identify and quantify the ND6
mRNA, RNA transfer hybridization experiments were carried
out with total cell RNA from three control cell lines (0913,
0923, and 1032) and three mutant cell lines (IV-5, IV-7, and
IV-15), using a [32P]dCTP-labeled ND6 mRNA-specific ssDNA
probe (synthesized by the Klenow DNA polymerase, using the
SP6 primer, from the pND6-1 plasmid; see Materials and Meth-
ods). After the blot was stripped, a 32P-labeled total HeLa cell
mtDNA probe was used to provide size markers and standards
for normalization purposes. These experiments revealed the
presence of an RNA species ;1.1 kb long and of another RNA
species ;2.4 kb long, as shown in Fig. 6a for two representative
control cell lines, 0923 and 1032, and two representative mu-
tant cell lines, IV-15 and IV-5. The ;1.1-kb RNA is equal in
size to the ND6 mRNA previously described in mouse (1.15 kb
FIG. 5. Quantification of the overall rates of synthesis of the mitochondrial
translation products after a 30-min [35S]methionine pulse in different lympho-
blastoid cell lines and relationship of the rates of synthesis of the individual
polypeptides to their serine (UCN) residue content. (a) Three independent
labeling experiments and two electrophoretic analyses of the mitochondrial
translation products after each labeling were performed for each cell line. The
individual values for the rates of overall mitochondrial protein labeling in the
various cell lines, determined as detailed in Materials and Methods, were nor-
malized relative to the value for 143B.TK2 cells in each gel, and the mean rel-
ative value for each cell line was expressed as a percentage of the average nor-
malized value obtained for the control cell lines, with error bars representing 2
standard errors of the mean. The horizontal dashed lines represent the average
value for the control and mutant cell lines, and the vertical arrows represent 2
standard errors of the mean for the two groups. P indicates the significance,
according to the ANOVA test, of the difference between mutant and control
values. (b) Relationship between the average rate of labeling of the individual
mitochondrial translation products in the mutant cell lines, expressed relative to
the average value in the control cell lines, and the number of serine (UCN) res-
idues that they contain. CYTB, apocytochrome b. (c) Relationship between
average relative rate of synthesis of the individual polypeptides in the mutant
cell lines and the proportion of serine (UCN) residues that they contain. The
curve shown describes the equation Rx 5 R0{0.1/[0.1(1 2 x) 1 1.5x]}, whose
parameters have been optimized to make the best fit to the data. In this equation,
Rx is the rate of labeling of a polypeptide having x proportion of serine (UCN)
residues in mutant cells relative to the rate in wild-type cells, the rates being
expressed as reciprocals of the times required for their synthesis (see text for
details).
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[6]) and rat cells (1.1 kb [42]) and is presumably the human
equivalent. As described for the mouse and rat equivalents, the
human ND6 mRNA is expected to encompass the 525-nt cod-
ing sequence and ;600 nt of the 39 untranslated sequence (Fig.
3). The 2.4-kb RNA could conceivably be a precursor of the
ND6 mRNA. On the other hand, the ND6 mRNA encoded in
the L-strand overlaps the ND5 mRNA encoded in the H-
strand (Fig. 3). The identical size of the 2.4-kb RNA species
and of the H-strand-encoded ND5 mRNA (29) raised the pos-
sibility that mispriming by the SP6 primer within the segment
of the ND5 mRNA coding sequence contained in the pND6-1
plasmid or within adjacent vector sequences could produce
a probe complementary to the ND5 mRNA. Indeed, when a
riboprobe specific for the ND6 mRNA, synthesized on the
pND6-1 plasmid template using the SP6 RNA polymerase, was
hybridized with the RNA on the stripped blot, only the band
corresponding to the ND6 mRNA was labeled (Fig. 6a). This
result strongly supported the ND5 identification of the 2.4-kb
RNA species.
In the experiment shown in Fig. 6a, the amount of ND6
mRNA is clearly lower in the two mutant cell lines than in the
control cell lines and to a similar extent in both the blot hy-
bridized with the ND6 mRNA-specific ssDNA probe and in
the blot hybridized with the ND6 riboprobe. To quantify the
ND6 mRNA in the various cell lines, the corresponding bands
in the blot hybridized with either of the two probes which is
shown in Fig. 6a and in another blot in which RNA prepara-
tions from the 0913 and IV-7 cell lines were similarly analyzed
were subjected to densitometric analysis. For comparison, the
levels of 16S and 12S rRNA, as representatives of the H-strand
rDNA transcription unit (Fig. 3), the combined levels of A6 or
A8 mRNA, COIII mRNA, COII mRNA, and ND3 mRNA, as
representatives of the whole H-strand transcription unit (28)
(Fig. 3), and the level of 7S RNA, the leader segment of the
L-strand polycistronic transcript (29), as representative of the
L-strand transcription unit (Fig. 3), were determined on the
same blots stripped and hybridized with the whole mtDNA
probe. The average levels of ND6 mRNA in the 0913, 0923,
and 1032 control cell lines and in the IV-15, IV-7, and IV-5
mutant cell lines were normalized to the average levels deter-
mined in the same cell lines for each of the individual or
combined reference RNAs and expressed relative to the cor-
responding average values obtained in the control cell lines
(Fig. 6b). The average relative levels of ND6 mRNA in the
three mutant cell lines tested, normalized with respect to the
12S rRNA or 16S rRNA or mRNAs, were fairly similar, rang-
ing between ;44% of the average control values (after nor-
malization to 12S rRNA) and ;47% (after normalization to
16S rRNA). These values reflected a very significant decrease
of the ND6 mRNA level in the 7445 mutation-carrying cell
lines (P , 0.0001 by the ANOVA test). The average relative
level of ND6 mRNA in the mutant cell lines was considerably
lower when normalized with respect to 7S RNA, i.e., ;28%.
This result may reflect a compensatory stimulation of L-strand
transcription in the mutant cell lines (see below). The averages
of the ND6 mRNA levels normalized to 12S rRNA or to 16S
rRNA or to mRNAs, expressed relative to the overall average
control values, were 43, 60, and 35% in the three mutant cell
lines IV-15, IV-7, and IV-5, respectively, and 123, 101, and
76% in the control cell lines 0913, 0923, and 1032, respectively.
Specific decrease in complex I-dependent respiration. The
total respiration capacities of the four control and four mutant
FIG. 6. Identification and quantification of the ND6 mRNA in control and mutant lymphoblastoid cell lines. (a) Equal amounts (20 mg) of total cell RNA from
the mutant cell lines IV-15 and IV-5 and the control cell lines 0923 and 1032 were electrophoresed through a 1.4% agarose-formaldehyde gel, transferred to a
Zeta-probe membrane, and hybridized first with a 32P-labeled ND6-specific ssDNA probe, and subsequently (after the blot was stripped) with a human mtDNA probe
32P labeled by random priming. After a further restripping of the blot, the RNA was rehybridized with an ND6-specific RNA probe (riboprobe). See Materials and
Methods for details. (b) Average relative ND6 mRNA content per cell normalized to the average content per cell of 7S RNA, 12S rRNA, 16S rRNA, and mRNAs in
three control cell lines (0913, 0923, and 1032) and three mutant cell lines (IV-15, IV-7, and IV-5). The values for the latter are expressed as percentages of the average
values for the control cell lines. Two independent determinations of ND6 mRNA content and one determination of the content of each of the four RNA reference
markers for each cell line were used in the calculations. Graph details and symbols are explained in the legend to Fig. 2b.
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cell lines were measured by determining the O2 consumption
rate in intact cells (Fig. 7a). The rate of total O2 consumption
in the four mutant cell lines revealed a variable decrease rel-
ative to the mean value measured in the wild-type cell lines;
this decrease ranged from ;10 to ;45%, with an average re-
duction of ;22% (P , 0.0001 by the ANOVA test). The vari-
ations in overall respiration among the individual control and
mutant cell lines showed a very significant correlation with the
corresponding variations in rate of mitochondrial protein syn-
thesis (r 5 0.94; P , 0.001).
In order to investigate which of the enzyme complexes of the
respiratory chain was affected in the mutant cell lines, O2
consumption measurements were carried out on digitonin-per-
meabilized cells, using different substrates and inhibitors (14).
As illustrated in Fig. 7b, in the mutant cell lines, the rate of
glutamate- and malate-driven respiration, which depends on
the activities of NADH:ubiquinone oxidoreductase (complex
I), ubiquinol-cytochrome c reductase (complex III), and cyto-
chrome c oxidase (complex IV) but usually reflects the rate-
limiting activity of complex I was very significantly decreased
relative to the average rate in the control cell lines, with de-
creases of 37 to 47% (;42% on the average; P , 0.0001 by the
ANOVA test). By contrast, the rate of succinate- and glycerol-
3-phosphate (G-3-P)-driven respiration, which depends on the
activities of complex III and complex IV but usually reflects the
activity of complex III, showed a decrease in the mutant cell
lines relative to the average control value, which was barely
significant (P 5 0.05). The rate of ascorbate–N,N,N9,N9-tetra-
methyl-p-phenylenediamine (TMPD)-driven respiration, which
reflects the activity of complex IV, showed a significant reduc-
tion in the mutant cell lines, relative to the average control
value (P 5 0.0166); here, however, a considerable contribution
to the decrease was given by the cell line V-7, which exhibited
an ;46% reduction, for unknown reasons. Figure 7c shows
that the glutamate- and malate-driven respiration rates of the
various mutant cell lines, normalized to their succinate- and
G-3-P-driven respiration rates, were very significantly de-
creased compared to the mean value in the control cell lines,
by an average of ;36% (P , 0.0001 by the ANOVA test). The
results discussed above strongly suggested that the most im-
portant effect of the mutation at position 7445 on the respira-
tory function of the mutant cell lines was a marked specific
decrease in the activity of complex I.
Growth properties of cell lines in glucose- or galactose-con-
taining medium. It has been shown that cell lines with im-
paired oxidative phosphorylation activity have reduced growth
capacity in medium containing galactose instead of glucose
(14, 15, 17). In order to investigate whether the respiratory
defects detected in the lymphoblastoid cell lines carrying the
mutation at position 7445 affected their growth capacity, the
DTs of the mutant cell lines in special DMEM-galactose and in
FIG. 7. Respiration and growth assays. (a) Average rates of total O2 con-
sumption per cell measured in different lymphoblastoid cell lines. Four to eight
determinations were carried out for each cell line. (b) Polarographic analysis of
O2 consumption in digitonin-permeabilized cells of different cell lines with dif-
ferent substrates. The activities of the various components of the respiratory
chain were determined as respiration dependent on glutamate or malate (Glu/
Mal) (solid bars; group averages indicated by dotted lines), succinate or glycerol-
3-phosphate (G-3-P) (Succ/G3P) (shaded bars; group averages indicated by
short-dash lines), or ascorbate plus TMPD (Asc/TMPD) (cross-hatched bars;
group averages indicated by long-dash lines). Three to eight determinations were
carried out for each cell line. (c) Ratios of glutamate and malate (glu1mal)-
driven respiration to succinate and G-3-P (succ1G–3–P)-driven respiration. (d)
Ratios of DTs in galactose-containing medium to DTs in glucose-containing
medium in different cell lines. Four determinations were carried out for each cell
line. Graph details and symbols are explained in the legend to Fig. 5a.
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special DMEM-glucose were compared to those of the control
cell lines in the same media. The DTs of the latter cell lines
were somewhat higher in galactose-containing medium (aver-
age, 52 h) than in glucose-containing medium (average, 45 h).
The DTs of the mutant cell lines in galactose-containing me-
dium, though showing considerably variation, exhibited a ten-
dency to be increased relative to the values in glucose-contain-
ing medium much more than observed in the control cell lines
(from an average of 68 h to an average of 95 h). The ratios of
DTs in galactose-containing medium to those in glucose-con-
taining medium showed a clear increase in the mutant versus
the control cell lines (from an average of ;1.15 to an average
of ;1.36; P 5 0.0002 by the ANOVA test) (Fig. 7d), confirm-
ing the existence of defective oxidative metabolism in the cells
carrying the mutation at position 7445. The variations in DT
ratio among the individual control and mutant cell lines were
inversely correlated with the rate of total O2 consumption (r 5
0.96; P , 0.001) and with the rate of mitochondrial protein syn-
thesis (r 5 0.91; P , 0.01).
DISCUSSION
Site and primary target of the mutation at position 7445.
The observation made in the present work that the mutant
and wild-type circularized mitochondrial tRNASer(UCN) had
an identical 59-39-end junction sequence lacking nt 7445 and
the results of experiments of in vitro processing of a synthe-
tic human tRNASer(UCN) by partially purified mitochondrial
RNase P have demonstrated that the mutation flanks the 39
end of the tRNA. Therefore, the revised structural model
originally proposed for bovine tRNA (47) also applies to the
human tRNASer(UCN). Furthermore, these findings have ex-
cluded the possibility that the mutation alters qualitatively the
processing of the primary transcript. Therefore, the most plau-
sible interpretation of the observed reduction in tRNASer(UCN)
level in the mutant cell lines is that it is due to an effect of the
mutation on the rate of processing of the primary transcripts,
in agreement with an earlier suggestion (33).
Pleiotropic secondary effects of the mutation at position
7445. It is reasonable to interpret the overall decrease in rate
of organelle-specific protein synthesis in the mutant cell lines
analyzed here as being due to the 62 to 77% reduction in the
level of total tRNASer(UCN) and to the corresponding expected
decrease in the amount of aminoacylated tRNASer(UCN). A
plot of the mitochondrial tRNASer(UCN) content in the various
control and mutant cell lines versus their rate of organelle-
specific translation has revealed a sharp threshold in the ca-
pacity of this tRNA to support protein synthesis. As shown in
Fig. 8, ;40% of the control level of the tRNASer(UCN) ap-
peared to be the minimum required to support the wild-type
rate of protein synthesis in mitochondria of the lymphoblastoid
cell lines. This threshold very probably accounts for the recent
report that the single lymphoblastoid cell line analyzed from
the Scottish pedigree, which exhibited a 60 to 65% decrease in
tRNASer(UCN) level, showed no significant decrease in overall
mitochondrial protein synthesis, although it exhibited a slight
reduction in growth rate in medium containing galactose ver-
sus glucose (33). It is interesting that previous work on cell
lines carrying the tRNALys gene A8344G transition associated
with the MERRF syndrome had indicated that ;50% of the
control level of aminoacylated tRNALys is the minimum re-
quired to support the rate of protein synthesis necessary for
full respiratory competence (9). Similarly, the presence of
;45% of wild-type mtDNA had been found to be the min-
imum allowing complementation of five missing tRNA genes
comprised in the 5-kbp mtDNA deletion associated with
chronic progressive external ophthalmoplegia (15). Therefore,
the available evidence strongly suggests that, in mammalian
mitochondria, there is not a large excess of tRNAs over the
levels allowing normal translation.
The markedly variable decrease in protein synthesis rate,
which has been observed in the present work in different mu-
tant cell lines, has clearly shown the important role that the
nuclear background plays in determining the severity of the
biochemical phenotype of mtDNA-linked diseases. This role
has been previously demonstrated for LHON, which is associ-
ated with ND gene mutations (19, 20, 43), and for the nonsyn-
dromic deafness associated with the 12S rRNA gene mutation
at position 1555 (14).
The present observations on the effects of the mutation at
position 7445 on mitochondrial protein synthesis differ from
those that have been previously made in mtDNA-less cell trans-
formants carrying in nearly homoplasmic form the tRNALys
A8344G mutation associated with the MERRF syndrome (9).
In these transformants, a reduction in the level of aminoacy-
lated tRNALys of 50 to 60% was found to cause a decrease in
overall rate of protein synthesis of 80 to 90%; furthermore, the
synthesis of the higher-molecular-weight translation products
was much more affected than that of the smaller products. By
contrast, in the cells carrying the mutation at position 7445, an
average decrease of ;45% in protein synthesis rate and no
significant difference in the labeling of the larger versus the
smaller mitochondrially synthesized polypeptides were ob-
served. In these cells, the lack of any effect of the absolute
serine (UCN) content on the rate of synthesis of the individual
mitochondrial translation products and the absence of any
abnormal translation products have clearly excluded any model
involving premature termination of translation at or near each
serine (UCN) codon, in contrast to what was previously shown
in cells carrying the tRNALys mutation at position 8344 (9). In
contrast, the transient-pause model, which assumes that ribo-
somes stall at each serine UCN codon for a certain time and
then resume elongation in the proper frame, has been found to
fit well the data on the relationship between reduction in la-
FIG. 8. Relationship between the relative level of tRNASer(UCN) and relative
rate of mitochondrial protein synthesis in mutant (solid circles) and wild-type
(open circles) cell lines. The values of each parameter for the different cell lines
are expressed as percentages of the average values for the control cell lines.
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beling of the various polypeptides and their proportion of
serine (UCN) residues.
The dropping-off propensity of mitochondrial tRNALys in
human cell lines carrying the MERRF mutation at position
8344 may be related to an unconventional anticodon confor-
mation, which has been associated, in both Escherichia coli and
mammalian cytosolic tRNALys species, with the occurrence of
hypermodified nucleotides in the wobble position 34 of the
anticodon and at position 37 (1, 41). Recently, these hyper-
modified nucleotides have also been identified in wild-type
human mitochondrial tRNALys (16).
As to the explanation for the much more pronounced de-
crease than expected from the transient-pause model which
was observed in the rate of synthesis of the ND6 polypeptide in
the cell lines carrying the mutation at position 7445, a crucial
observation made in the present work is the significant reduc-
tion in these cell lines in the amount of the ND6 mRNA. This
reduction does not appear to be due to a decrease in the rate
of synthesis of this RNA. In fact, the significantly larger
amount of 7S RNA, the leader segment of the L-strand poly-
cistronic transcript (27), in the mutant cell lines relative to
those of the control cell lines argues rather in favor of an
increase, possibly compensatory, in the rate of L-strand tran-
scription. Therefore, the finding of a strong decrease in ND6
mRNA level in the mutant cell lines points to a reduced
stability of the ND6 mRNA precursor. This interpretation
provides strong support for the idea that the more marked
deficiency in the synthesis of the ND6 subunit compared to
the other mtDNA-encoded polypeptides in the mutant cells
is related to the processing defect of the tRNASer(UCN) pre-
cursor. This idea, as discussed below, is based on the fact that
the ND6 mRNA is derived from the same precursor as the
tRNASer(UCN) (29, 30).
Among the L-strand polycistronic transcripts of HeLa cell
mtDNA, three overlapping polyadenylated RNA species,
RNAs 1, 2, and 3 (29, 30), had been previously identified,
which correspond with their common 59 end to the 59 end of
the ND6 reading frame, and extend for ;10,400, ;7,070, and
;4,155 nt, respectively (Fig. 3). Of these, RNA 2 is by far the
most abundant (4, 13) and extends up to the tRNASer(UCN)
without including it (29, 30). The processing of the fast turning-
over mtDNA L-strand transcripts is a highly regulated phe-
nomenon, which ensures both the accurate cleavages leading
to the formation of eight L-strand-encoded tRNAs and of the
ND6 mRNA and the controlled disposal of the large excess of
transcripts (4). In this process, the order of the cleavage events
may play a determining role. In vitro tRNA processing exper-
iments (36) and in vivo observations (12, 37) have indicated
that the order of 59- and 39-end cleavages of the tRNA pre-
cursors in human mitochondria may vary depending on the
tRNA. Other in vitro processing experiments utilizing partially
purified mitochondrial RNase P from HeLa cells have shown
that a tRNASer(UCN) precursor carrying a 39-terminal CCA is
accurately cleaved by the enzyme at the 59 end of the tRNA
(32a). This result is consistent with the idea that, in the for-
mation of the tRNASer(UCN), the 39-end cleavage by the mito-
chondrial 39 endonuclease precedes the 59-end cleavage by the
mitochondrial RNase P, which is possibly a regulated step (Fig.
9). Furthermore, it is well established that all RNA species
other than tRNAs which are derived from the processing of the
primary mtDNA transcripts are polyadenylated (30). There-
fore, the hypothesis that a failure in tRNASer(UCN) processing
and the consequent lack of stabilization by polyadenylation of
the upstream L-strand transcript segment (RNA 2), encom-
passing the ND6 mRNA, would lead to the degradation of the
latter RNA is very plausible (Fig. 9). The occurrence, which
was mentioned above, of a mechanistic link between the pro-
cessing defect of the tRNASer(UCN) precursor and the de-
creased stability of the ND6 mRNA precursor is strongly sup-
ported by the observation that the amount of ND6 mRNA in
three control and three mutant cell lines was correlated with
the tRNASer(UCN) level (r 5 0.923; P , 0.01). The results
reported here thus represent a striking example of long-dis-
tance effects of a posttranscriptional event.
Effects of the mutation at position 7445 on respiration. In
the control and mutant cell lines analyzed here, there was a
very significant correlation between the rate of mitochondrial
protein synthesis, on one hand, and overall respiratory capacity
(P , 0.001) or relative growth rate in galactose- versus glucose-
containing medium (P , 0.01), on the other. This correlation
is clearly consistent with an important role that the marked
decrease in tRNASer(UCN) steady-state level in the mutant cell
lines plays in producing their overall respiration and growth
defects. On the other hand, a very significant reduction (P ,
0.0001) in glutamate- or malate-dependent O2 consumption
has been observed in the mutant cell lines compared to the
control cell lines. This reduction contrasted with a marginal-
ly significant decrease in the same cell lines in complex III-
and IV-dependent O2 consumption and pointed to a specific
NADH dehydrogenase deficiency. These observations have
called attention to the possibility of another factor(s) being
involved in the respiratory phenotype of these cell lines. The
evidence presented here strongly suggests that one such factor
is the significant reduction in the level of ND6 mRNA caused
by the mutation, which accentuates the decrease in rate of
synthesis of the ND6 subunit beyond the general effect on
mitochondrial protein synthesis caused by the tRNASer(UCN)
depletion. Recent work on cultured mutant mouse cells carry-
ing different proportions of mtDNA with a nonsense mutation
in the gene encoding another subunit of NADH dehydroge-
FIG. 9. Model illustrating the possible role of the tRNASer(UCN) precursor
processing on the stabilization by polyadenylation of the L-strand transcript
RNA 2. See text for details.
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nase, ND5, has shown that the glutamate- or malate-depen-
dent respiration declines in these mutants in parallel with the
rate of synthesis of ND5, indicating that the synthesis of this
subunit is nearly rate-limiting for respiration (5a). The obser-
vation made in the present work that an ;59% average de-
crease in rate of synthesis of the ND6 subunit in the mutant
cell lines is associated with an average reduction of ;42% in
glutamate- or malate-dependent respiration suggests that the
above conclusion concerning the ND5 subunit also applies to
the ND6 subunit. These findings support the conclusion that,
in mammalian mitochondria, there is not a large excess of
protein synthesis over the rate necessary to support normal
respiration. Other work on mouse cells has shown that the
ND6 subunit is essential for the assembly and function of
complex I (5). Furthermore, several mutations in the ND6
gene have been shown to cause diseases in humans. Thus, a
mutation at position 14,484 (24) has been found to be associ-
ated with LHON, and a mutation at position 14,459 (44) or a
combination of mutations at positions 4,160 and 14,484 (20)
has been found to be associated with LHON and dystonia.
Possible synergistic role of ND gene mutations. Another
factor which may play a synergistic role in the establishment of
the respiratory phenotype of the mutant cell lines is the occur-
rence in these of several homoplasmic mtDNA mutations af-
fecting subunits of NADH dehydrogenase. Among these com-
plex I subunit mutations, that in the ND1 gene at position 4216
(which changes a nonconserved tyrosine to a histidine) and
that in the ND5 gene at position 13708 (which changes a
moderately conserved alanine to a threonine) belong to the
group of so-called secondary LHON mutations (22). These
mutations confer upon an individual a lower risk for develop-
ing LHON than any of the primary LHON mutations (occur-
ring in the ND4 gene at position 11708, in the ND1 gene at
position 3460, in the ND6 gene at position 14459 or 14484, and
in the apocytochrome b gene at position 15257) (23, 44), and it
has been proposed that they can act synergistically with such
primary mutations. The results of a recent haplotype and phy-
logenetic analysis has indeed suggested that the best candidate
for increasing the penetrance of primary LHON mutations is
the ancient combination of mutations at positions 4216 and
13708 (40), which has also been found in the present deafness
pedigree (11). Another sequence change found in the present
work in the ND3 gene of the mutant cell lines at position 10084
(which changes an isoleucine to a threonine) is a previously
undescribed rare mutation. In the New Zealand pedigree, the
clinical disorder has higher penetrance than in the Scottish
pedigree, and it is reasonable to suggest that these coexisting
mutations may be responsible.
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